CL2021001685A1 - Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar - Google Patents
Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantarInfo
- Publication number
- CL2021001685A1 CL2021001685A1 CL2021001685A CL2021001685A CL2021001685A1 CL 2021001685 A1 CL2021001685 A1 CL 2021001685A1 CL 2021001685 A CL2021001685 A CL 2021001685A CL 2021001685 A CL2021001685 A CL 2021001685A CL 2021001685 A1 CL2021001685 A1 CL 2021001685A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- treatment
- palmoplantar pustulosis
- pustulosis
- palmoplantar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785316P | 2018-12-27 | 2018-12-27 | |
| US201962815431P | 2019-03-08 | 2019-03-08 | |
| US201962891464P | 2019-08-26 | 2019-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001685A1 true CL2021001685A1 (es) | 2022-02-18 |
Family
ID=69190739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001685A CL2021001685A1 (es) | 2018-12-27 | 2021-06-23 | Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20200207862A1 (enExample) |
| EP (1) | EP3902604A1 (enExample) |
| JP (1) | JP2022515480A (enExample) |
| KR (1) | KR20210119407A (enExample) |
| CN (1) | CN113301955A (enExample) |
| AU (1) | AU2019416727A1 (enExample) |
| BR (1) | BR112021010789A2 (enExample) |
| CA (2) | CA3265173A1 (enExample) |
| CL (1) | CL2021001685A1 (enExample) |
| IL (1) | IL284259A (enExample) |
| MX (1) | MX2021007807A (enExample) |
| PH (1) | PH12021551540A1 (enExample) |
| TW (1) | TW202037604A (enExample) |
| WO (1) | WO2020136101A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10526410B2 (en) | 2015-04-15 | 2020-01-07 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (IL-36R) |
| AU2019236105B2 (en) | 2018-03-14 | 2025-07-31 | Boehringer Ingelheim International Gmbh | Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis |
| US11730812B2 (en) | 2019-03-08 | 2023-08-22 | Boehringer Ingelheim International Gmbh | Anti-IL-36R antibody formulations |
| MX2023000763A (es) * | 2020-07-17 | 2023-02-13 | Boehringer Ingelheim Int | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. |
| AU2021353854A1 (en) * | 2020-09-30 | 2023-05-04 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| BR112023014103A2 (pt) * | 2021-03-04 | 2023-10-10 | Boehringer Ingelheim Int | Métodos para o tratamento de gpp |
| EP4305207A2 (en) | 2021-03-12 | 2024-01-17 | Boehringer Ingelheim International GmbH | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| MX2023012903A (es) * | 2021-05-03 | 2023-11-08 | Boehringer Ingelheim Int | Metodo para producir spesolimab. |
| EP4337257A1 (en) * | 2021-05-12 | 2024-03-20 | AnaptysBio, Inc. | Antibody composition |
| WO2023285362A1 (en) * | 2021-07-12 | 2023-01-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-36 inhibitors for the treatment of netherton syndrome |
| EP4638492A2 (en) * | 2022-12-23 | 2025-10-29 | Icosavax, Inc. | Antibodies against metapneumovirus fusion (f) protein and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2009040602A1 (en) | 2007-09-25 | 2009-04-02 | Becton Dickinson France | Autoinject0r with deactivating means moveable by a safety shield |
| SI2780373T1 (sl) | 2011-11-16 | 2019-12-31 | Boehringer Ingelheim International Gmbh | Protitelesa proti IL-36R |
| CH705992A2 (de) | 2012-10-11 | 2013-06-14 | Tecpharma Licensing Ag | Injektionsvorrichtung. |
| US10526410B2 (en) * | 2015-04-15 | 2020-01-07 | Anaptysbio, Inc. | Antibodies directed against interleukin 36 receptor (IL-36R) |
| US11690956B2 (en) | 2015-04-24 | 2023-07-04 | Shl Medical Ag | Sub-assembly of a medicament delivery device and a medicament delivery device |
| CH711066A2 (de) | 2015-05-13 | 2016-11-15 | Tecpharma Licensing Ag | Verbesserte Injektionsvorrichtung. |
| JP6654773B2 (ja) * | 2015-12-25 | 2020-02-26 | 国立大学法人名古屋大学 | インターロイキン３６受容体アンタゴニスト欠損症の治療薬 |
| AU2019236105B2 (en) * | 2018-03-14 | 2025-07-31 | Boehringer Ingelheim International Gmbh | Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis |
-
2019
- 2019-12-20 KR KR1020217023769A patent/KR20210119407A/ko not_active Withdrawn
- 2019-12-20 MX MX2021007807A patent/MX2021007807A/es unknown
- 2019-12-20 US US16/722,133 patent/US20200207862A1/en not_active Abandoned
- 2019-12-20 CA CA3265173A patent/CA3265173A1/en active Pending
- 2019-12-20 BR BR112021010789-4A patent/BR112021010789A2/pt not_active Application Discontinuation
- 2019-12-20 CA CA3124996A patent/CA3124996A1/en active Pending
- 2019-12-20 TW TW108147070A patent/TW202037604A/zh unknown
- 2019-12-20 JP JP2021537716A patent/JP2022515480A/ja active Pending
- 2019-12-20 AU AU2019416727A patent/AU2019416727A1/en not_active Abandoned
- 2019-12-20 WO PCT/EP2019/086521 patent/WO2020136101A1/en not_active Ceased
- 2019-12-20 CN CN201980087043.9A patent/CN113301955A/zh active Pending
- 2019-12-20 EP EP19842584.5A patent/EP3902604A1/en active Pending
-
2021
- 2021-06-21 IL IL284259A patent/IL284259A/en unknown
- 2021-06-23 CL CL2021001685A patent/CL2021001685A1/es unknown
- 2021-06-26 PH PH12021551540A patent/PH12021551540A1/en unknown
-
2022
- 2022-08-10 US US17/818,723 patent/US20230131364A1/en not_active Abandoned
- 2022-11-10 US US18/054,303 patent/US20230115617A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3902604A1 (en) | 2021-11-03 |
| US20200207862A1 (en) | 2020-07-02 |
| US20230115617A1 (en) | 2023-04-13 |
| CA3265173A1 (en) | 2025-10-31 |
| KR20210119407A (ko) | 2021-10-05 |
| CN113301955A (zh) | 2021-08-24 |
| MX2021007807A (es) | 2021-08-11 |
| BR112021010789A2 (pt) | 2021-08-31 |
| US20230131364A1 (en) | 2023-04-27 |
| PH12021551540A1 (en) | 2022-02-21 |
| AU2019416727A1 (en) | 2021-07-22 |
| TW202037604A (zh) | 2020-10-16 |
| CA3124996A1 (en) | 2020-07-02 |
| JP2022515480A (ja) | 2022-02-18 |
| WO2020136101A1 (en) | 2020-07-02 |
| IL284259A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551540A1 (en) | Anti-il-36r antibodies for treatment of palmoplantar pustulosis | |
| CL2020002342A1 (es) | Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| MX2018014231A (es) | Metodos y composiciones para tratar canceres resistentes al inhibidor de la via de cinasas proteicas activadas por mitogeno (mapk), no cinasas extracelulares de señal regulada (erk). | |
| CL2025000404A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| MX2020009862A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX2016016800A (es) | Metodos para el tratamiento del sobrepeso o la obesidad. | |
| CL2021003422A1 (es) | Anticuerpos anti il-13ra2 y usos de los mismos (divisional 201902323). | |
| MX2018015089A (es) | Combinacion de linagliptina y metformina. | |
| PE20160123A1 (es) | Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio | |
| CL2020000812A1 (es) | Semaglutida en la terapia médica. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO7000770A2 (es) | Terapia combinada para el tratamiento del cáncer de ovario | |
| MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. | |
| UY36663A (es) | Anticuerpos anti-ap2 y agentes de unión al antígeno para tratar trastornos metabólicos | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| CL2023003562A1 (es) | Anticuerpos y composiciones anti-nkg2a | |
| MX2023014500A (es) | Medicamento para el tratamiento y/o prevencion de cancer. |